All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.

The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your MPN Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL Hub

ALL Hub

AML Hub

AML Hub

GvHD Hub

GvHD Hub

Lupus Hub

Lupus Hub

Lymphoma Hub

Lymphoma Hub

Multiple Myeloma Hub

Multiple Myeloma Hub

PsOPsA Hub

PsOPsA Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact
TypesTherapeuticsCongressesTrialsExpert OpinionsDRUG UPDATES
2020-02-11T15:31:02.000Z

PROUD-PV/CONTINUATION-PV studies: benefits of ropeg IFN alfa-2b for the treatment of PV

By Alia Mohamed
Featured
Jean-Jacques Kiladjian
Feb 11, 2020
Share:

Bookmark this article

The MPN Hub were pleased to speak to Jean-Jacques Kiladjian, University of Paris, Paris, FR, during the 61st American Society of Hematology (ASH) meeting in Orlando, US. Based on the PROUD-PV/CONTINUATION-PV studies, we asked: What are the benefits of ropeginterferon alpha-2b for the treatment of polycythemia vera?

Jean-Jacques Kiladjian discusses the results of the phase III, randomized, PROUD-PV and its extension study, CONTINUATION-PV, in patients with polycythemia vera in need of a cytoreductive treatment such as the long-acting ropeginterferon alpha-2b. He explains the response rates, clinical benefits and superiority of the ropeginterferon alpha-2b treatment against the comparator arm.

PROUD-PV/CONTINUATION-PV studies: benefits of ropeg IFN alfa-2b for the treatment of PV

More about...
ASH 2019CONTINUATION-PVHydroxyureaJAK2 driver mutationsMPN driver mutationsMyeloproliferative neoplasmsPolycythemia veraPROUD-PVRopeginterferon alfa-2b

Related articles

Add bookmark

Treatment-free remission as a new goal for patients with PV

We summarize a presentation by Francesca Palandri outlining the treatment goals for patients diagnosed with polycythemia vera, and review whether treatment-free remission is a viable option...

Jul 7, 2023
Add bookmark

Treatment-free remission as a new goal for patients with PV

We summarize a presentation by Francesca Palandri outlining the treatment goals for patients diagnosed with polycythemia vera, and review...

Jul 7, 2023
Add bookmark

Ropeginterferon alfa-2b is effective and safe in patients older than 60 years with PV

As discussed in our last editorial theme, the pegylated forms of interferon-alpha improve treatment compliance and lower the needed dosing. This leads to a better...

Jan 21, 2021
Add bookmark

Ropeginterferon alfa-2b is effective and safe in patients older than 60 years with PV

As discussed in our last editorial theme, the pegylated forms of interferon-alpha improve treatment compliance...

Jan 21, 2021

Newsletter

Subscribe to get the best content related to MPN delivered to your inbox